Plasminogen activators and their inhibitor in bone tumors and tumor-like damages.
作者： N. E. Kushlinskii , A. I. Yusifov , E. S. Gershtein , Yu. N. Solov'ev , N. N. Trapeznikov
关键词:
摘要: Expression of urokinase- and tissue-type plasminogen activators their inhibitor PAI-1 in the cytosolic fraction 20 osteosarcomas, chondrosarcomas, 13 giant-cell bone tumors, 5 Ewing's sarcomas, 7 osteochondral exostoses was studied by enzyme immunoassay. The content urokinase-type activator increased, while concentration decreased tumors various histological compositions compared to exostoses. A positive correlation found between volume osteo- chondrosarcomas. increased patients with primary osteosarcomas characterized early generalization pathological process.
springer.com
sci-hub.se 参考文章(9)
P. Mignatti, D. B. Rifkin, Biology and biochemistry of proteinases in tumor invasion Physiological Reviews. ,vol. 73, pp. 161- 195 ,(1993) , 10.1152/PHYSREV.1993.73.1.161
Michael J Duffy, Catherine Duggan, Hugh E Mulcahy, Enda W McDermott, Niall J O’Higgins, Urokinase plasminogen activator: a prognostic marker in breast cancer including patients with axillary node-negative disease Clinical Chemistry. ,vol. 44, pp. 1177- 1183 ,(1998) , 10.1093/CLINCHEM/44.6.1177
Nicolai Grebenschikov, Fred Sweep, Anneke Geurts, Peter Andreasen, Hans De Witte, Susanne Schousboe, Joop Heuvel, Theo Benraad, ELISA for complexes of urokinase-type and tissue-type plasminogen activators with their type-1 inhibitor (uPA-PAI-1 and tPA-PAI-1). International Journal of Cancer. ,vol. 81, pp. 598- 606 ,(1999) , 10.1002/(SICI)1097-0215(19990517)81:4<598::AID-IJC16>3.0.CO;2-9
Carsten G. H�ckel, Sabine Krueger, Hans-J�rgen Grote, Yumi Oshiro, Sherie Hodges, Dennis A. Johnston, Mark E. Johnson, Albert Roessner, Alberto G. Ayala, Bogdan Czerniak, Overexpression of cathepsin B and urokinase plasminogen activator is associated with increased risk of recurrence and metastasis in patients with chondrosarcoma. Cancer. ,vol. 89, pp. 995- 1003 ,(2000) , 10.1002/1097-0142(20000901)89:5<995::AID-CNCR8>3.0.CO;2-8
CGJ Sweep, J Geurts-Moespot, N Grebenschikov, JH de Witte, JJTM Heuvel, M Schmitt, MJ Duffy, F Jänicke, MD Kramer, JA Foekens, N Brünner, G Brugal, AN Pedersen, ThJ Benraad, External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts. British Journal of Cancer. ,vol. 78, pp. 1434- 1441 ,(1998) , 10.1038/BJC.1998.704
MAXIME P. LOOK, JOHN A. FOEKENS, Clinical relevance of the urokinase plasminogen activator system in breast cancer. Apmis. ,vol. 107, pp. 150- 159 ,(1999) , 10.1111/J.1699-0463.1999.TB01538.X
J Pöllänen, O Saksela, EM Salonen, P Andreasen, L Nielsen, K Danø, A Vaheri, Distinct localizations of urokinase-type plasminogen activator and its type 1 inhibitor under cultured human fibroblasts and sarcoma cells Journal of Cell Biology. ,vol. 104, pp. 1085- 1096 ,(1987) , 10.1083/JCB.104.4.1085
Anton C. W. de Bart, Paul H.A. Quax, Clemens W.G.M. Löwik, Jan H. Verheijen, Regulation of plasminogen activation, matrix metalloproteinases and urokinase-type plasminogen activator-mediated extracellular matrix degradation in human osteosarcoma cell line MG63 by interleukin-1 alpha Journal of Bone and Mineral Research. ,vol. 10, pp. 1374- 1384 ,(2009) , 10.1002/JBMR.5650100915
Joan C Castellote, Enric Grau, Maria A Linde, Nuria Pujol-Moix, Miquel LI Rutllant, Detection of both type 1 and type 2 plasminogen activator inhibitors in human monocytes. Thrombosis and Haemostasis. ,vol. 63, pp. 67- 71 ,(1990) , 10.1055/S-0038-1645688